

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A substantially pure human Bcl-X<sub>L</sub>-binding polypeptide, said polypeptide ~~comprising the sequence selected from the group~~ consisting of the sequence of any of SEQ ID NOS: 4-50, and 63-71, and 224-228.
2. (Previously Presented) A substantially pure human Bcl-X<sub>L</sub>-binding polypeptide, said polypeptide comprising the sequence selected from the group consisting of SEQ ID NOS: 51-62, 229, and 230.
- 3-26. (Cancelled).
27. (New) A substantially pure human Bcl-X<sub>L</sub>-binding polypeptide, said polypeptide consisting of the sequence of any of SEQ ID NOS: 224-228.
28. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 51.
29. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 52.
30. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 53.
31. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 54.
32. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 55.
33. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 56.
34. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 57.

35. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 58.
36. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 59.
37. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 60.
38. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 61.
39. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 62.
40. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 229.
41. (New) The substantially pure human Bcl-X<sub>L</sub>-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 230.